Cefozopran is a fourth-generation cephalosporin antibiotic primarily used in the treatment of various bacterial infections. It is effective against a wide range of Gram-positive and Gram-negative bacteria, making it suitable for infections in the respiratory tract, urinary tract, skin, abdomen, and bloodstream. It is also utilized in managing septicemia, ventilator-associated pneumonia, and other severe infections where broad-spectrum antibiotic coverage is required, especially in immunocompromised patients or those at risk of resistant strains. In clinical settings, it is often administered intravenously for optimal efficacy, particularly in hospitalized patients with serious infections. Its strong activity and good tissue penetration make it ideal for difficult-to-treat infections. Its role in combating resistant bacterial strains has also been noted, though its use is carefully monitored to prevent the development of further resistance.